daclizumab HYP

Known as: daclizumab high-yield process 
 

Topic mentions per year

Topic mentions per year

2013-2015
01220132015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
AIM Daclizumab high yield process (HYP) is a humanized IgG1 monoclonal antibody that binds to the α-subunit of the interleukin-2… (More)
  • table 2
  • table 4
  • table 5
  • figure 1
Is this relevant?
2016
2016
BACKGROUND AND OBJECTIVES Daclizumab high-yield process (HYP) is a humanized IgG1 monoclonal antibody that binds to the α-subunit… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 1
Is this relevant?
Review
2016
Review
2016
BACKGROUND The SELECT study demonstrated superior effects of daclizumab high-yield process (DAC HYP) to placebo in key endpoints… (More)
Is this relevant?
2016
2016
INTRODUCTION Cutaneous adverse events (AEs) have been observed in clinical studies of daclizumab high-yield process (HYP) in… (More)
  • figure 1
  • table 1
  • table 1
  • table 2
  • table 3
Is this relevant?
2015
2015
BACKGROUND Daclizumab high-yield process (HYP) is a humanized monoclonal antibody that binds to CD25 (alpha subunit of the… (More)
  • table 1
  • table 2
  • table 3
  • table 3
Is this relevant?
2015
2015
OBJECTIVE To assess the relationship between CD56(bright) natural killer (NK) cells and multiple sclerosis (MS) disease activity… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2014
2014
BACKGROUND In the SELECT trial, disease activity was reduced in patients with multiple sclerosis who received daclizumab high… (More)
Is this relevant?
2014
2014
BACKGROUND AND OBJECTIVE Daclizumab is a humanized monoclonal antibody that blocks the α-subunit of the interleukin-2 receptor… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Daclizumab, a humanised monoclonal antibody, modulates interleukin-2 signalling by blocking the α subunit (CD25) of… (More)
Is this relevant?
2013
2013
The results of the SELECT trial, recently published in The Lancet, indicate that the humanized monoclonal antibody daclizumab… (More)
Is this relevant?